Sex-specific Difference for Small Cell Lung Cancer from Immunotherapy Advancement
Open Access
- 31 May 2024
- journal article
- research article
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 60, S13-S21
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposideLung Cancer, 2023
- Lung Cancer Screening by Race and Ethnicity in an Integrated Health System in HawaiiJAMA Network Open, 2022
- Global Patterns and Trends in Lung Cancer Incidence: A Population-Based StudyJournal of Thoracic Oncology, 2021
- First investigation of the prevalence of parvoviruses in slaughterhouse pigs and genomic characterization of ungulate copiparvovirus 2 in VietnamArchives of Virology, 2021
- Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized CohortJournal of Thoracic Oncology, 2020
- Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032Journal of Thoracic Oncology, 2019
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialThe Lancet, 2017
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trialThe Lancet Oncology, 2016
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and SurvivorshipMayo Clinic Proceedings, 2008
- Permutation tests for joinpoint regression with applications to cancer ratesStatistics in Medicine, 2000